Log in with your email address username.

×

Important notice

doctorportal Learning is on the move as we will be launching a new website very shortly. If you would like to sign up to dp Learning now to register for CPD learning or to use our CPD tracker, please email support@doctorportal.com.au so we can assist you. If you are already signed up to doctorportal Learning, your login will work in the new site so you can continue to enrol for learning, complete an online module, or access your CPD tracker report.

To access and/or sign up for other resources such as Jobs Board, Bookshop or InSight+, please go to www.mja.com.au, or click the relevant menu item and you will be redirected.

All other doctorportal services, such as Find A Doctor, are no longer available.

Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis

Prostate cancer screening using the prostate-specific antigen (PSA) test has been available to asymptomatic men in Australia since the late 1980s; however, substantial uncertainty still remains over the net benefit of early detection.

Based on the trial evidence available to date,1 routine PSA screening for asymptomatic men is not recommended in Australia;2 however, access to PSA testing is available and publically subsidised in Australia through the Medicare Benefits Schedule. The Royal Australian College of General Practitioners (RACGP) recommends that general practitioners assist men seeking PSA screening to reach informed decisions by weighing the potential benefits of screening against the inconvenience and harms of biopsies resulting from false-positive PSA test results, as well as the side effects of unnecessary surgery and/or radiotherapy for indolent cancers that currently cannot be reliably distinguished from those of a more aggressive nature.2

While debate continues about the interpretation of existing trial data in decisions about the PSA screening of asymptomatic men in general, there is a recognition that the trade-off between…

email